![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SCI-110 is an innovative proprietary combination drug candidate, formulated to treat the symptoms related to diseases of the central nervous system.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: SCI-110
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2021